Clinical trial
Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic…
NCT00006467 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00006467 |
|---|---|
| Title | Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas |
| Official title | Phase II Trial of Gemcitabine and ISIS 2503 in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | ISIS 2503, gemcitabine hydrochloride |
| Enrollment | 48 |
| Start date | Feb 1, 2001 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | Mar 8, 2004 |
| Last update posted | Jul 6, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: